A British study showed that both a direct-to-consumer app and an app used for scientific purposes failed to recognise rare skin cancers.
Ligelizumab for adolescents with chronic spontaneous urticaria, insufficiently controlled with antihistamines, did not raise new safety concerns.
In different skin models, key receptors could be identified whose modulation can help in creating compromised-skin topicals against SARS-CoV-2 entry.
According to studies, more than two-thirds of schoolchildren have headaches on a regular basis. Around 20% of children and adolescents repeatedly miss lessons as a result.
The assessment of a novel anti-OX40 antibody resulted in substantial reductions in Eczema Area and Severity Index scores in a recent trial.
A study published in JAMA investigated whether adding antithrombotic therapy to placebo reduced major cardiopulmonary complications over a 45-day treatment period in COVID-19 outpatients.
For atopic dermatitis with less than 10% body surface area involvement, difelikefalin has exhibited significant efficacy in itch reduction.
A study linked genital warts and human leukocyte antigen systems. Protective and risk alleles could be identified as future antiviral or vaccine targets.
A dose-ranging study showed that oral treatment with the JAK3 inhibitor ritlecitinib is efficacious in reducing depigmented areas in the face.
A elderly-focused subanalysis of phase 3 trials revealed IGA-TS in 60.5% of atopic dermatitis patients applying 1.5% ruxolitinib cream over 8 weeks.
What influence do cardiological, social or neurological problems have on psychiatric diseases and vice versa? This question was addressed by the speakers at the symposium "Recognising and treating psychiatric comorbidities".
A trial showed abrocitinib superiority over dupilumab in fast itch control and skin clearance in adult patients with moderate-to-severe atopic dermatitis.
A long-term assessment of topical tapinarof found a high rate of complete disease clearance as well as a lasting response up to 52 weeks.
Ritlecitinib was able to induce regrowth of hair in the ALLEGRO study. The effect was seen even in patients with alopecia universalis.
Two phase 3 trials have demonstrated the efficacy of the topical JAK1/JAK2 inhibitor ruxolitinib in the therapy of vitiligo. The cream was well tolerated.
The physician-patient relationship has been going through a profound crisis for years, with consequences not only for individual health but also for public health. We met with Prof. Fabrizio Asioli to talk about the issue.
The once-daily deucravacitinib showed maintenance of response through week 52 in phase 3 POETYK PSO-1 and POETYK PSO-2 trials.
A registry study revealed no differences in respiratory tract infections risks across biologics, including the newer IL-17 and IL-23 inhibitors.
Remibrutinib showed promise with early-onset and further maintained action in chronic spontaneous urticaria, with many reaching a well-controlled disease.
A trial that compared upadacitinib with dupilumab in adults with moderate-to-severe AD demonstrated benefits in shifting to the inhibitor.